Bio-IT World April 20, 2021
The United States lags behind at least 30 countries in terms of the sequencing it has done throughout the pandemic, according to data deposited into GISAID and reported by Nature. This is a bit surprising considering the breadth of US expertise and equipment
Thermo Fisher Scientific provides both NGS sequencing technology platforms as well as SARS-CoV-2 diagnostic tests with FDA early use authorization. From this vantage point, the company sees the range of pandemic-response testing, and Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific, sees a few reasons why sequencing is lagging.
“I think part of [the delay] was really how to coordinate—we have so many states here—how to coordinate sequencing at state and public health...
Today's Sponsors
Today's Sponsor